SCM
HRTX icon

Suvretta Capital Management’s Heron Therapeutics HRTX Stock Holding History

Suvretta Capital Management’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-53,000
Closed -$622K – 92
2020
Q1 		$622K Buy
+53,000
New +$996K 0.02% 58

Other funds holding HRTX

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Suvretta Capital Management's HRTX Position: Q4 2022 in Review

Suvretta Capital Management sold out of Heron Therapeutics (HRTX) in Q4 2022, closing a stake of 2,807,000 shares — an estimated $11.8M sold.

Suvretta Capital Management first reported a position in HRTX in Q1 2020 and held it in 8 quarters. The position peaked at $23.1M in Q2 2021. 176 funds tracked by Wall St. Rank hold HRTX as of Q4 2022.

  • Suvretta Capital Management reported no remaining Heron Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Suvretta Capital Management sold 2,807,000 Heron Therapeutics shares in Q4 2022, an estimated $11.8M.
  • Suvretta Capital Management first reported a position in Heron Therapeutics in Q1 2020 and held it in 8 quarters.
  • Suvretta Capital Management's Heron Therapeutics position peaked at $23.1M in Q2 2021.
  • 176 funds tracked by Wall St. Rank held Heron Therapeutics as of Q4 2022.

Based on Suvretta Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.